
I tried to stay away from Cyclospora today.
Saturday is the one day of the week when nothing moves. The health departments that report daily do not report on weekends, CDC’s outbreak page has said 1,947 illnesses and 98 hospitalizations since July 24, and the fifty-state total I keep sat at 21,452 from Friday afternoon straight through to dinner. A day off, I thought. Then I ordered a salad, and here I am at the keyboard.
What sent me back was not a case count. It was a study a private company published on July 30 that nobody in Atlanta or College Park has matched. Truveta is a Seattle outfit owned by a consortium of American health systems, and it sits on the electronic health records those systems generate. Its research arm went and looked at every healthcare encounter carrying a cyclosporiasis diagnosis from January 1, 2018 through July 27, 2026, counting each patient once per illness episode.
Here is what they found. In July 2026, the rate of cyclosporiasis diagnosis reached 10.5 per 100,000 people who had a healthcare encounter that month. The average July rate across 2018 through 2025 was 0.9. That is an eleven-fold increase over the historical average, and more than eight times the worst July anywhere in the eight-year series, which was 1.2 per 100,000 in 2018.
Understand why that particular number matters, because it is the answer to an objection I have been handed at least a dozen times this month. Every time I write about the scale of this outbreak, somebody in the industry explains to me that it is an artifact of better testing. Multiplex PCR stool panels have been spreading through American labs since 2014, they say, and a parasite that was invisible for decades is finally being seen. There is truth in that, and I have said so. But it explains a trend line, not this. Truveta is measuring a rate, and the denominator is people who walked into a healthcare setting. A wider installed base of panels can bend a curve over ten years. It cannot make July 2026 eight times worse than the worst July in the same dataset, drawn from the same health systems, coded the same way.
The severity numbers are the other half, and they are the part I did not expect. Twenty-two percent of patients with a cyclosporiasis diagnosis had an emergency department visit within two weeks of that diagnosis. Nearly one in eight, 11.9 percent, was hospitalized. Among adults sixty-five and older the hospitalization rate was 19.4 percent, against 9.9 percent for everyone younger — almost double.
Now set that beside what the produce industry is telling consumers. The International Fresh Produce Association’s consumer FAQ on Cyclospora says outcomes are generally favorable even in immunocompromised patients, and that no significant long-term health consequences have been reported. I will set that claim against a number: one in eight of the people who got this diagnosis went into a hospital bed.
Truveta is a commercial data company, not a public health agency, and this is a research blog post that is preliminary and not peer reviewed. Cases were identified by diagnosis code, not by laboratory confirmation, so this is not CDC’s case definition, and the two counts are not interchangeable. Most important, the population is people who sought care and got diagnosed, which skews toward more severe illness. That is almost certainly why 11.9 percent is roughly double the federal ratios — 98 hospitalizations among 1,947 outbreak cases is 5.0 percent, and the 423 among 6,707 lab-confirmed cases on the surveillance page is 6.3 percent. Truveta states every one of those limitations in its own write-up, which is more than can be said for some of the numbers circulating in this outbreak. It adds one more: July data were incomplete when the analysis ran, so the July rate is likelier to be too low than too high.
One finding has stayed with me all evening. Most of those emergency department visits happened before or on the day of diagnosis. People were already in acute care before anyone knew what they had. That is the reporting lag seen from inside the exam room instead of from the epidemic curve — the patient is dehydrated and frightened in an emergency department while the stool specimen is still in transit, and the case will not reach a state count for weeks after that. Diarrhea showed up in 74.6 percent of these patients, abdominal pain in 23 percent, nausea or vomiting in 18.8 percent, dehydration in 6.3 percent. The clinical picture is exactly what CDC describes, and it can run for weeks untreated.
Here is what bothers me about the whole thing. We now have four parallel counting systems for one outbreak. Fifty state health departments publish 21,452 cases between them. CDC’s surveillance page publishes 6,707 lab-confirmed plus more than 11,500 awaiting confirmation or further analysis. CDC’s outbreak page publishes 1,947 and has not moved that number in more than a week — through a Friday on which Michigan alone added 387 cases. And a private company a ferry ride from my office, with no statutory duty to anybody, turned around a severity profile in a matter of days that no federal agency has produced in three months. Truveta did not do anything heroic. It queried a database.
The season CDC recognizes runs May 1 through August 31. There are thirty days left in it, and when it closes the counts will flatten and the reporters will go home, and the question of what made all these people sick will still be open.
I finally ate the salad. It was cold by then, and it was fine. It was also grown somewhere by someone, washed with something, in water that came from somewhere, and there is not a person in this country who can tell me whose it was. That is not a consumer problem. Washing will not fix it, and neither will a list of foods to avoid. It is a traceability problem, a water problem, and a counting problem, and every one of those is fixable by people who have chosen not to fix it.










